Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Nephrogenic systemic fibrosis is a new, rare disease of unknown cause that affects patients with renal failure. Single cases led to the suspicion of a causative role of gadodiamide that is used for magnetic resonance imaging. This study therefore reviewed all of the authors' confirmed cases of nephrogenic systemic fibrosis (n = 13) with respect to clinical characteristics, gadodiamide exposure, and subsequent clinical course. It was found that all had been exposed to gadodiamide before the development of nephrogenic systemic fibrosis. The delay from exposure to first sign of the disease was 2 to 75 d (median 25 d). Odds ratio for acquiring the disease when gadodiamide exposed was 32.5 (95% confidence interval 1.9 to 549.2; P < 0.0001). Seven (54%) patients became severely disabled, and one died 21 mo after exposure. No other exposure/event than gadodiamide that was common to more than a minority of the patients could be identified. These findings indicate that gadodiamide plays a causative role in nephrogenic systemic fibrosis.

[1]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.

[2]  G. Krestin,et al.  Non-tissue Specific Extracellular MR Contrast Media , 2006 .

[3]  M. Luyckx,et al.  Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. , 1996, Methods and findings in experimental and clinical pharmacology.

[4]  F. Mendoza,et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. , 2006, Seminars in arthritis and rheumatism.

[5]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  F. Nestle,et al.  Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis , 2005, The British journal of dermatology.

[7]  R. Swartz,et al.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.

[8]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[9]  H. Thomsen.  Gadolinium Contrast Media for Radiographic Examinations , 2006 .

[10]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[11]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[12]  S. Kazanjian,et al.  Gadolinium-enhanced magnetic resonance angiography of renal transplants. , 1997, Magnetic resonance imaging.

[13]  D. Worah,et al.  Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. , 1993, Investigative radiology.

[14]  B. Hillman.  Research in Radiology Departments , 1993, Investigative radiology.

[15]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[16]  R. Perriss,et al.  Preliminary experience with contrast-enhanced MR angiography in patients with end-stage renal failure. , 2005, Academic radiology.